Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

Pfizer Inc. CEO Albert Bourla is set to meet with activist investor Starboard Value amid growing pressure to revitalize the ...

Pfizer CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday, citing ...

Shares of Pfizer (NYSE: PFE) have been stuck in the mud since December 2022, with its shares down more than 45% over that ...

Pfizer (PFE) discontinues development of experimental RSV therapy sisunatovir from pipeline in a blow for its $525M ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Albert Bourla, the CEO of pharmaceutical company Pfizer ($PFE), plans to meet with activist investor Starboard Value in ...

Starboard has a roughly $1 billion stake in the drugmaker and approached former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio, both of whom expressed interest in supporting the activist investor's ...

Pfizer’s 2023 U.S.-booked air volume increased $17.4 million from the prior year. Of that volume, 55 percent was for internal travel and 41 percent was for domestic travel. Following a full return to ...

Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at ... But despite the cultural ubiquity, Viagra has recently faced the inevitable threat from competition ...

Influenza causes 140,000 to 710,000 hospitalisations and 12,000 to 52,000 deaths in the US every year, as well as economic losses of around $25 billion a year, according to Pfizer.